Image of SARS-CoV2 Virus with Text: Resources for A/I Clinicians

A Message from the AAAAI

As the COVID-19 pandemic continues, the AAAAI remains committed to providing you with resources that will help you navigate this difficult period. Our comprehensive set of resources includes the latest information on virus variants, talking to your patients about the COVID-19 vaccines, vaccine reactions, and more. 

Important Update SymbolRochelle P. Walensky, MD, MPH, Director of the Centers for Disease Control and Prevention (CDC)
Rochelle P. Walensky, MD, MPH, Director of the CDC, provided a brief virtual presentation at the 2023 AAAAI Annual Meeting. Her focus was the specialty and COVID-19. Watch the video.

Guidance from the ADT Interest Section for Performing Pulmonary Office Procedures During the Pandemic
A work group report from the AAAAI's Asthma Diagnosis and Treatment (ADT) Interest Section on pulmonary office procedures is now available from JACI: In Practice. This work group report has diligently reviewed all aspects of office, community and patient considerations in approaching such procedures. Read the report here.

If you are an AAAAI member and have any specific questions regarding the treatment of patients or management of your practice, please contact us at practicematters@aaaai.orgAny patients with medical questions are advised to consult their own physician provider. 

Important Update SymbolRead all messages from the AAAAI COVID-19 Response Task Force

COVID-19 Vaccines and Treatments

Check this section regularly for new developments related to vaccines and treatments for COVID-19. With studies showing that patients trust their personal physicians, allergists are in a position to discuss the risks and benefits of getting vaccinated with their patients, especially considering the unique expertise of the allergist in evaluating allergic reactions to vaccines, as well as in recognizing and treating anaphylaxis. 

Summaries of Key Topics

Virus Variants

Treatment and Medications

Talking to Your Patients About the COVID-19 Vaccine

Vaccine Reactions

Comprehensive Resource Document on Vaccines from the AAAAI’s Advocacy partner, Hart Health Strategies

Vaccine Data and Approvals

Monoclonal Antibodies and Other Treatments

Member Questions Answered by the Task Force

Additional Vaccines Resources

Resources for A/I Clinicians

Your Patients ImageImage with Link to Patient InformationImage with Links to Webinars, Podcasts and More CME Opportunities
Your Practice ImageImage with Link to Dispelling MythsImage with Link to Clinician Wellness & Resilience



COVID-19 Information in AAAAI Resources

AAAAI Journals

Journal of Allergy and Clinical Immunology Home 

 JACI In Practice Logo

COVID-19 the Theme for the April 2023 JACI

Journal cover


Ask the AAAAI about COVID-19

The AAAAI invites members to send your COVID-19 questions to Questions and responses that might be helpful for a wider audience are provided in the links below. Any patients with medical questions are advised to consult their own physician provider.

Ask Us - Email practicematters@aaaai.orgAdministering Immunotherapy


Immunocompromised Patients

Other Important Issues


Disclaimer: The AAAAI COVID-19 Response Task Force answers questions from medical professionals to provide general information for medical professionals to consider in applying their own independent clinical judgement, and the AAAAI will not be liable for any circumstances arising from a medical professional’s use or reliance upon this information. Provision of this information does not give rise to a physician-patient relationship. Any patients with medical questions are advised to consult their own physician provider.

Advocacy Updates

Image of U.S. Capitol Building with text Frequent Updates from our Advocacy Team

The Department of Health and Human Services (HHS) ended the Public Health Emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service (PHS) Act, on May 11, 2023. Review this Hart Health Strategies, Inc. summary of key excerpts of federal agency policy changes, including on telehealth and remote services, physician supervision, and other relevant policies, due to its end.